Aelis Farma Secures €458k Grant for Obesity Program

Aelis Farma, a biopharmaceutical company in Bordeaux, has been awarded a €458,000 grant under the France 2030 initiative in Nouvelle-Aquitaine. This funding aims to bolster the company's research into obesity and related metabolic diseases. The non-dilutive support falls under the Projets d’Avenir Innovation scheme, emphasizing the project's scientific and innovative merits.

The funds will advance the preclinical development of new drugs targeting the CB1 receptor, thought to play a role in obesity-related disorders. This initiative highlights Aelis Farma's potential in pioneering treatments in strategically significant therapeutic areas.

CEO Pier Vincenzo Piazza regards the grant as a milestone that validates the program's scientific quality and innovation. The company expresses gratitude towards the French State, the Nouvelle-Aquitaine Region, and Bpifrance for their backing, facilitating Aelis Farma's progress in developing novel therapeutic innovations.